Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. More Details
Average dividend payer and fair value.
Share Price & News
How has Pfizer's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PFE is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PFE's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: PFE matched the US Pharmaceuticals industry which returned 7.4% over the past year.
Return vs Market: PFE underperformed the US Market which returned 22.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Pfizer's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall StShareholders Of Pfizer (NYSE:PFE) Must Be Happy With Their 37% Return
2 weeks ago | Simply Wall StKey Things To Consider Before Buying Pfizer Inc. (NYSE:PFE) For Its Dividend
1 month ago | Simply Wall StDividend Investors: Don't Be Too Quick To Buy Pfizer Inc. (NYSE:PFE) For Its Upcoming Dividend
Is Pfizer undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PFE ($40.8) is trading below our estimate of fair value ($65.82)
Significantly Below Fair Value: PFE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PFE is poor value based on its PE Ratio (26.1x) compared to the US Pharmaceuticals industry average (21.8x).
PE vs Market: PFE is poor value based on its PE Ratio (26.1x) compared to the US market (19.4x).
Price to Earnings Growth Ratio
PEG Ratio: PFE is poor value based on its PEG Ratio (6.6x)
Price to Book Ratio
PB vs Industry: PFE is good value based on its PB Ratio (3.5x) compared to the US Pharmaceuticals industry average (3.6x).
How is Pfizer forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PFE's forecast earnings growth (4% per year) is above the savings rate (2.2%).
Earnings vs Market: PFE's earnings (4% per year) are forecast to grow slower than the US market (21.8% per year).
High Growth Earnings: PFE's earnings are forecast to grow, but not significantly.
Revenue vs Market: PFE's revenue (3.3% per year) is forecast to grow slower than the US market (10.2% per year).
High Growth Revenue: PFE's revenue (3.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PFE's Return on Equity is forecast to be high in 3 years time (27.3%)
How has Pfizer performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PFE has a large one-off loss of $6.4B impacting its September 27 2020 financial results.
Growing Profit Margin: PFE's current net profit margins (17.9%) are lower than last year (30.5%).
Past Earnings Growth Analysis
Earnings Trend: PFE's earnings have grown by 14% per year over the past 5 years.
Accelerating Growth: PFE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PFE had negative earnings growth (-46.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16.8%).
Return on Equity
High ROE: PFE's Return on Equity (13.3%) is considered low.
How is Pfizer's financial position?
Financial Position Analysis
Short Term Liabilities: PFE's short term assets ($47.7B) exceed its short term liabilities ($34.2B).
Long Term Liabilities: PFE's short term assets ($47.7B) do not cover its long term liabilities ($79.3B).
Debt to Equity History and Analysis
Debt Level: PFE's debt to equity ratio (94.4%) is considered high.
Reducing Debt: PFE's debt to equity ratio has increased from 58.2% to 94.4% over the past 5 years.
Debt Coverage: PFE's debt is well covered by operating cash flow (20.3%).
Interest Coverage: PFE's interest payments on its debt are well covered by EBIT (11.4x coverage).
What is Pfizer current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PFE's dividend (3.73%) is higher than the bottom 25% of dividend payers in the US market (1.48%).
High Dividend: PFE's dividend (3.73%) is low compared to the top 25% of dividend payers in the US market (4.14%).
Stability and Growth of Payments
Stable Dividend: PFE's dividends per share have been stable in the past 10 years.
Growing Dividend: PFE's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (95.8%), PFE's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: PFE's dividends in 3 years are forecast to be well covered by earnings (49.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Albert Bourla (58 yo)
Dr. Albert Bourla, DVM, Ph.D. serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 and has been its Executive Director since February 23, 2018. Dr. Bourla was Chief Operating Officer ...
CEO Compensation Analysis
Compensation vs Market: Albert's total compensation ($USD17.93M) is above average for companies of similar size in the US market ($USD10.98M).
Compensation vs Earnings: Albert's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
|Chairman of the Board & CEO||1.92yrs||US$17.93m||0.0015% |
|Group President & Chief Business Officer||8.5yrs||US$8.96m||0.0076% |
|CFO & Executive VP of Global Supply||13.25yrs||US$11.08m||0.0076% |
|Chief Scientific Officer and President of Worldwide Research||1.92yrs||US$9.60m||no data|
|Senior VP||0.75yr||no data||0.00014% |
|Executive VP and Chief Digital & Technology Officer||1.92yrs||no data||0.00078% |
|Senior Vice President of Investor Relations||12.5yrs||no data||no data|
|Executive VP & General Counsel||7yrs||no data||0.0014% |
|Executive VP and Chief Compliance||7yrs||no data||0.0013% |
|Chief Development Officer & Executive VP of Global Product Development||4.75yrs||no data||0.0022% |
|Executive VP & Chief Human Resources Officer||no data||no data||0.00040% |
|MD & Regional President of Oncology||no data||no data||no data|
Experienced Management: PFE's management team is seasoned and experienced (5.9 years average tenure).
|Chairman of the Board & CEO||1.92yrs||US$17.93m||0.0015% |
|Lead Independent Director||2.67yrs||US$400.00k||no data|
|Independent Director||3.83yrs||US$350.00k||0.00023% |
|Independent Director||13.25yrs||US$380.00k||0.00018% |
|Independent Director||6.5yrs||US$380.00k||0.000060% |
|Member of Emerging Markets Advisory Board||no data||no data||no data|
|Independent Director||0.75yr||no data||no data|
|Independent Director||2.75yrs||US$344.70k||no data|
|Independent Director||0.83yr||no data||no data|
|Independent Director||1.5yrs||US$231.62k||0.000070% |
|Independent Director||5.5yrs||US$365.00k||no data|
|Independent Director||9yrs||US$383.60k||no data|
Experienced Board: PFE's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pfizer Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Pfizer Inc.
- Ticker: PFE
- Exchange: NYSE
- Founded: 1849
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$226.783b
- Shares outstanding: 5.56b
- Website: https://www.pfizer.com
Number of Employees
- Pfizer Inc.
- 235 East 42nd Street
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PFE||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Jan 1968|
|PFE *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jan 1968|
|0Q1N||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jan 1968|
|PFE||OM (OMX Nordic Exchange Stockholm)||Yes||Common Stock||SE||SEK||Jan 1968|
|PFE||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1968|
|PFE||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Jan 1968|
|PFE||BVC (Bolsa de Valores de Colombia)||Yes||Common Stock||CO||COP||Jan 1968|
|PFES||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Stock||GB||SEK||Jan 1968|
|PFE||SNSE (Santiago Stock Exchange)||Yes||Common Stock||CL||USD||Jan 1968|
|PF-U||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Jan 1968|
|PFE||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Jan 1968|
|PFE||BVL (Bolsa de Valores de Lima)||Yes||Common Stock||PE||USD||Jan 1968|
|US_PFE_||KAS (Kazakhstan Stock Exchange)||Yes||Common Stock||KZ||KZT||Jan 1968|
|PFE||BASE (Buenos Aires Stock Exchange)||CEDEAR EACH 2 REP 1 ORD USD0.05||AR||ARS||Sep 2000|
|PFIZ34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 4 REP 1 COM||BR||BRL||May 2011|
|PFE.WI||NYSE (New York Stock Exchange)||COM||US||USD||Nov 2020|
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Ch...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/03 00:04|
|End of Day Share Price||2020/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.